Effects of the angiotensin converting enzyme inhibitor benazepril in cats with induced renal insufficiency

American Journal of Veterinary Research

Volumn 62, Issue 3, 2001, Pages 375-383

  Brown, Scott A ^a   Brown, Cathy A ^a   Jacobs, Gilbert ^a   Stiles, Jean ^a   Hendi, Rim S ^a   Wilson, Shawn ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOHIPPURIC ACID; BENAZEPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY PRESSURE; CAT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLOMERULUS CAPILLARY; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HYPERTENSION; INULIN CLEARANCE; KIDNEY BIOPSY; KIDNEY FAILURE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN;

ANIMALIA; FELIS CATUS; GLOMERULUS;

EID: 0035095445     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2001.62.375     Document Type: Article

References (42)

1. Brenner BM, Meyer TW, Hostetter TH. The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982;307:652-659.
2. Brown SA, Crowell WA, Brown CA, et al. Pathophysiology and management of progressive renal disease. Br Vet J 1997;154: 93-109.
3. Hostetter TH, Olson JL, Rennke HG, et al. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981;241:F85-F92.
4. Fries JW, Sandstrom DJ, Meyer TW, et al. Glomerular hypertrophy and epithelial cell injury modulate progressive glomerulosclerosis in the rat. Lab invest 1989;60:205-218.
5. Brown SA, Brown CA. Single-nephron adaptations to partial renal ablation in cats. Am J Physiol 1995;269:R1002-R1008.
6. Maschio G, Alberti D, Janin G, et al. Effect of angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-945.
7. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77:1993-2000.
8. Jackson B, Whitty M, Debrevi L, et al. Preservation of renal structure and function in the rat remnant kidney model of chronic renal failure by enalapril treatment. Pathology 1987;19:38-42.
9. Brown SA, Walton CA, Crawford P, et al. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993;43:1210-1218.
10. Gaber L, Walton C, Brown S, et al. Effects of antihypertensive agents on the morphologic progression of diabetic nephropathy in dogs. Kidney Int 1994;46:161-169.
11. Brown S, Langford K, Tarver S. Effects of certain vasoactive agents on the long-term pattern of blood pressure, heart rate, and motor activity in cats. Am J Vet Res 1997;58:647-652.
12. King JN, Humbert-Droz E, Maurer M. Plasma angiotensin converting enzyme activity and pharmacokinetics of benazepril and benazeprilat in cats after single and repeated oral administration of benazepril HC1. J Vet Pharmacol Therap 1999;22:360-367.
13. Brown SA. Determinants of glomerular ultrafiltration in cats. AmJ Vet Res 1993;54:970-975.
14. Brown SA, Finco DR, Crowell WA, et al Single-nephron adaptations to partial renal ablation in the dog. Am J Physiol 1990; 258:F495-F503.
15. Thomas LA, Brown SA. Relationship between colloid osmotic pressure and plasma protein concentration in cattle, horses, dogs, and cats. Am J Vet Res 1992;53:2241-2244.
16. Navar LG, Bell PD, White RW, et al. Evaluation of the single nephron glomerular filtration coefficient in the dog. Kidney Int 1977;12:137-149.
17. Brown SA, Finco DR, Crowell WA, et al. Dietary protein intake and the glomerular adaptations to partial nephrectomy in dogs. J Nutr 1991;121:S125-S127.
18. Arendshorst WJ, Gottschalk CW. Glomerular ultrafiltration dynamics: euvolemic and plasma volume-expanded rats. Am J Physiol 1980;239:F171-F186.
19. Finn WF. Compensatory renal hypertrophy in Sprague-Dawley rats :glomerular ultrafiltration dynamics. Ren Physiol 1982;5:222-234.
20. Ennulat D, Brown S. Canine and equine mesangial cells in vitro. In Vitro Cell Dev Biol Anim 1995;31:574-578.
21. Morgan RV Systemic hypertension in four cats: ocular and medical findings. J Am Anim Hosp Assoc 1986;22:615.
22. Kobayashi DL, Peterson ME, Graves TK, et al. Hypertension in cats with chronic renal failure or hyperthyroidism. J Vet Intern Med 1990;4:58-62.
23. Turner J, Brogdon J, Lees G, et al. Idiopathic hypertension in a cat with secondary hypertensive retinopathy associated with a high-salt diet. J Am Anim Hosp Assoc 1990;26:647-651.
24. Lesser M, Fox PR, Bond BR. Assessment of hypertension in 40 cats with left ventricular hypertrophy by Doppler-shift sphygmomanometry. J Small Anim Pract 1992;33:55-58.
25. Littman M. Spontaneous systemic hypertension in 24 cats. J Vet Intern Med 1994;8:79-86.
26. Stiles J, Polzin D, Bistner S. The prevalence of retinopathy in cats with systemic hypertension and chronic renal failure or hyperthyroidism. J Am Anim Hosp Assoc 1994;30:564-572.
27. Jensen J, Henik RA, Brownfield M, et al. Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease. Am J Vet Res 1997;58:535-540.
28. Henik RA, Snyder PS, Volk LM. Treatment of systemic hypertension in cats with amlodipine besylate. J Am Anim Hosp Assoc 1997;33:226-234.
29. Mishina M, Watanabe T, Fujii K, et al. Non-invasive blood pressure measurements in cats: clinical significance of hypertension associated with chronic renal failure. J Vet Med Sci 1998;60:805-808.
30. Snyder PS. Amlodipine: a randomized, blinded clinical trial in 9 cats with systemic hypertension. J Vet Intern Med 1998;12: 157-162.
31. Sander C, Horauf A, Reusch C. Indirect blood pressure measurement in cats with diabetes mellitus, chronic nephropathy and hypertrophic cardiomyopathy. Tierarztl Prax Ausg K Klientiere Heimtiere 1998;26:110-118.
32. Taugner F, Baatz G, Nobiling R. The renin-angiotensin system in cats with chronic renal failure. J Comp Pathol 1996;115: 239-252.
33. Braam B, Mitchell KD, Fox J, et al. Proximal tubular secretion of angiotensin II in rats. Am J Physiol 1993;264:F891-F898.
34. Anderson S, Meyer TW, Rennke HG, et al. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin invest 1985:76:612-619.
35. Dworkin LD, Benstein JA, Parker M, et al. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms Kidney Int 1993;43:808-814.
36. Anderson S, Brenner BM. Therapeutic implications of converting-enzyme inhibitors in renal disease. Am J Kidney Dis 1987; 10:81-87.
37. Anderson S, Diamond J, Karnovsky MJ, et al. Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome. J Clin Invest 1988; 82:1757-1768.
38. Yoshida Y, Fogo A, Ichikawa I. Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int 1989;35:654-660.
39. Cooper G, Tomanek RJ. Model dependent behaviour of pressure hypertrophied myocardium. Cardiovasc Res 1987;21:342-351.
40. Adams LG, Polzin DJ, Osborne CA, et al. Effects of dietary protein and calorie restriction in clinically normal cats and in cats with surgically induced chronic renal failure. Am J Vet Res 1993;54: 1653-1662.
41. Finco DR, Brown SA, Brown CA, et al. Protein and calorie effects on progression of induced chronic renal failure in cats. Am J Vet Res 1998;59:575-582.
42. Elliott J, Barber PJ. Feline chronic renal failure: clinical findings in 80 cases diagnosed between and 1995. J Small Anim Pract 1998;1992;39:78-85.